Skip to main content
LITTLE GREEN PHARMA LTD logo

LITTLE GREEN PHARMA LTD — Investor Relations & Filings

Ticker · LGP ISIN · AU0000074924 ASX Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2022-02-09 Regulatory Filings
Country AU Australia
Listing ASX LGP

About LITTLE GREEN PHARMA LTD

https://www.littlegreenpharma.com/

Little Green Pharma Ltd is a vertically integrated medicinal cannabis company focused on the cultivation, production, and distribution of pharmaceutical-grade cannabis medicines. The company operates advanced cultivation and manufacturing facilities, producing a diverse range of products including oils and dried flower. Adhering to Good Manufacturing Practice (GMP) standards, it ensures product consistency and safety across its entire supply chain, from genetics and breeding to final delivery. Little Green Pharma serves both domestic and international markets, maintaining a significant presence in Europe, including Germany and the United Kingdom. The company is committed to advancing clinical research and development to support the therapeutic use of cannabis for various medical conditions, focusing on patient-centric care and high-quality delivery systems.

Recent filings

Filing Released Lang Actions
Notice of Release from Escrow 2 pages 222.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 10 February 2022 titled 'NOTICE OF RELEASE FROM ESCROW' pursuant to ASX Listing Rule 3.10A. It details the release of securities from escrow, listing the types and quantities of securities to be released. The document is short (3199 characters) and is a regulatory announcement about securities release, not a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is not a report publication announcement since it is the actual announcement of a securities release event. The content fits best under a general regulatory announcement category related to compliance and securities status updates. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-02-09 English
Intention to Demerge Psychedelics Business 4 pages 648.1KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 8 February 2022 regarding the intention of Little Green Pharma Ltd (LGP) to demerge its psychedelics business into a separate unlisted entity, Reset Mind Sciences Ltd. It details the rationale, benefits, leadership, and next steps for the demerger, including shareholder approvals and entitlement offers. The document does not contain financial statements or detailed financial performance data but rather strategic corporate actions and plans. It is a formal announcement about a corporate restructuring event and related financing plans (entitlement offer). This fits best under the category of Capital/Financing Update (CAP), as it involves a significant capital restructuring and shareholder entitlement offer related to the demerger. The document is lengthy and detailed, not a brief notice or a simple regulatory filing, and it is not a full financial report or earnings release.
2022-02-07 English
Company Update Presentation 24 pages 4.2MB
Investor Presentation Classification · 95% confidence The document is a detailed company update presentation from Little Green Pharma Ltd dated 2 February 2022. It contains extensive information about the company's business model, market position, sales growth, product innovation, manufacturing capabilities, shareholder structure, and financial highlights such as cash reserves and market capitalization. The content is structured as a presentation with slides, including disclaimers, forward-looking statements, and investment highlights. There are no indications that this is a full annual or interim financial report with detailed financial statements, nor is it a transcript, audit report, or regulatory filing. The document is clearly a presentation aimed at investors, focusing on financials, strategy, market position, and growth plans. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-02-01 English
Quarterly Activities Report & Appendix 4C 11 pages 962.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report and Appendix 4C' for the period ending December 2021. It contains detailed operational highlights, financial figures such as revenue and cash receipts for the quarter, updates on clinical studies, regulatory updates, and financing information. The presence of substantive financial data for a quarter, including revenue, cash receipts, and cash balances, indicates this is a comprehensive interim financial report. The document is about 15,000 characters long, which is substantial and not a mere announcement or certification. The content aligns with the definition of an Interim / Quarterly Report (IR), which includes comprehensive financial data and analysis for a period shorter than a full fiscal year. Therefore, the correct classification is IR with high confidence. Q2 2022
2022-01-26 English
Exclusive Distribution Agreement for LGP Medicines in Greece 3 pages 534.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 21 January 2022 about Little Green Pharma signing an exclusive distribution agreement with PharmaServe Hellas for medicinal cannabis products in Greece. It details the terms of the agreement, market context, and company background. There are no financial statements, quarterly or annual results, or regulatory certifications. The content focuses on a business development and partnership agreement, which is a capital or financing update related to distribution and market expansion. It is not a full financial report, earnings release, or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7005 characters) and content confirm it is a substantive announcement, not a brief report publication announcement or regulatory filing.
2022-01-20 English
Exclusive Cannabis Oils Distribution Agreement in Germany 3 pages 560.5KB
Capital/Financing Update Classification · 90% confidence The document is an announcement dated 19 January 2021 from Little Green Pharma Ltd regarding the signing of an exclusive distribution agreement with a German distributor, AMP. The content focuses on the terms of the distribution agreement, marketing capabilities, and company background. There are no financial statements, regulatory certifications, or detailed financial performance data included. The document is a corporate announcement about a commercial agreement rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Capital/Financing Update (CAP) because it relates to a significant commercial agreement that impacts the company's distribution and potentially its revenue streams, which is typical for capital or financing updates involving strategic partnerships or contracts.
2022-01-18 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.